Altimmune Reports $480 Million in Cash as Third-Quarter Loss Widens

Altimmune, Inc. reported $480 million in cash, cash equivalents and investments as of Sept. 30, 2026, while its third-quarter net loss rose to $31.6 million from $19 million a year earlier.

Research and development expenses increased to $27 million from $15 million, mainly because of the PERFORMA and RESTORE trials.

PERFORMA is a global Phase 3 trial testing investigational pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH). Altimmune expects 52-week topline results in 2029.

Enrollment is complete in RESTORE, a Phase 2 trial of pemvidutide for alcohol-associated liver disease. Altimmune expects topline data in the second half of 2027.